Phase 2 N=1,500 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Ebola Virus
Primary: Serious Adverse Events. — 6; 6; 8 Participants — p=0.68
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Efficacy, Pharmacokinetics and Safety of Testosterone
Testicular Hypogonadism
Primary: Responder Rate - the Percentage of Subjects Whose Minimum Concentration Observed (Cmin) and Average Steady State Concentration (Cave) of Serum Testosterone Levels Were…
Phase 2 N=43 Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia
Peritoneal Carcinomatosis
Primary: The Grouped Miller and Payne (MP) System for Pathological Response: G1 (Minimal Changes and < 30% Cells Tumour Reduction That Includes MP G1-G2), G3 (Microscopic Foci…
Phase 2 N=5 A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
Progeria · Hutchinson-Gilford Syndrome
Primary: The Primary Objective of This Study is to Evaluate the Feasibility of Administering Intravenous Zoledronic Acid, Oral Pravastatin and Oral Lonafarnib, to Patients With…
Phase 2 N=82 Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
Breast Cancer
Primary: Cardiac Toxicity of Weekly Taxol Given With Weekly Herceptin When Delivered Immediately Following Four Cycles of Standard Dose AC. — 1; 8; 3; 11 Participants
Phase 2 N=49 Collection of Transplant Stem Cells for Plasma Cell Myeloma
Plasma Cell Myeloma · Multiple Myeloma
Primary: Percentage of Patients Achieving at Least 2 x 10^6 Cluster of Differentiation 34 (CD34) Cells Per Kg Recipient Body Weight on Day 1 of Apheresis — 98 percentage of…
Phase 2 N=165 Randomized Clinical Trial of Skin Closure With Staples Versus Suture
Wound Infection · Wound Complication
Primary: Number of Participants With Wound Disruption or Infection (Wound Complications) Occurring Within 4-8 Weeks of the Date of the Primary Surgery. — 28; 25 Participants
Phase 2 N=49 Apnea, Bariatric Surgery Versus Continuous Positive Airway Pressure (CPAP) Trial
Obstructive Sleep Apnea · Obesity
Primary: Effective Apnea Hypopnea Index — 29.5; 20.0 Events per hour
Phase 2 N=31 Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Number of Participants With an Average Increase in ALSFRS-R Score of One Point Per Month — 0 Participants
Phase 2 N=109 A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
Oral Mucositis
Primary: Duration of Severe Oral Mucositis (SOM) — 18; 9; 14; 22 days
Phase 2 N=100 Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
Patients at Risk for Melanoma
Primary: UV-induced Oxidative Stress in Irradiated and Unirradiated Nevi — 94.6; 96.2; 33.6; 33.1 percentage of 8-OG expression in nevi — p=.65
Phase 2 N=251 Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 54.6; 60.7 ml per square meter of body-surface area — p=0.18
Phase 2 N=69 Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 91.3 percentage of participants
Phase 2 N=78 Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL
Metabolic Syndrome
Primary: Mean Increase in High Density Lipoprotein Cholesterol (HDL-C) at Baseline and 12 Weeks — 37.4; 36.2; 40.6; 44.2 mg/dL — p=<0.0001
Phase 2 N=1,050 Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine
Infections, Streptococcal · Streptococcal Infections
Primary: Concentration of Serotype Ia GBS IgG Levels in Healthy Non-pregnant Women — 6.81; 6.66 µg/mL